Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT05976568
PHASE2/PHASE3

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Sponsor: Qilu Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the efficacy and safety of QL1706 in combination with bevacizumab and/or chemotherapy versus sintilimab in combination with bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.

Official title: A Phase II/III, Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of QL1706 in Combination With Bevacizumab and/or Chemotherapy Versus Sintilimab in Combination With Bevacizumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

668

Start Date

2023-09-01

Completion Date

2027-09-01

Last Updated

2023-08-04

Healthy Volunteers

No

Interventions

DRUG

QL1706

7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

DRUG

Bevacizumab

15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

DRUG

Oxaliplatin injection

85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle

DRUG

Capecitabine

1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle

DRUG

Sintilimab

200 mg administered as IV infusion on Day 1 of each 21-day cycle

Locations (2)

Nanjing Tianyinshan Hospital

Nanjing, Jiangsu, China

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, China